Global Continuous Glucose Monitoring (2018 to 2024) - Featuring Abbott Laboratories, Beta Bionics & Biolinq Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Continuous Glucose Monitoring: The Current State of the Art" report has been added to ResearchAndMarkets.com's offering.

The scope of this study includes what a CGM is, how it works and how a PWD wears the device. This study also includes advances in the technology - both those advances being seen in the market today and advances for which CE mark or FDA approval is pending. There is a section covering the pancreas and diabetes, including the continued growth in the number of diabetics and prediabetics in the U.S. and elsewhere. It covers selected clinical trials pertaining to the evolution and proliferation of CGMs. The scope of this report includes novel CGMs and components in development. These may or may not ever see a market launch but should nonetheless be of interest to industry managers.

Also covered here are selected regulatory and reimbursement affairs. Regulatory guidelines need to keep abreast of the technological developments so that safe, effective devices may enter the market. Without sufficient, carefully crafted reimbursement or payer coverage, the devices will never get off the ground. Both favorable regulatory and reimbursement guidelines are needed if manufacturers are to continue to develop and commercialize the best equipment for managing diabetes.

Selected companies are profiled in this report. These include not only the market leaders - Dexcom, Medtronic, Abbott, Tandem, and Insulet - but also smaller companies working on promising technology.

Not covered in the scope of this report is an in-depth analysis of market values and growth rates. These are available in other reports by the publisher. Also not covered is the ultimate in the artificial pancreas: the cell-based implant. While these are under development, for practical purposes implants seem to be some distance down the road.

Companies Mentioned

  • Abbott Laboratories
  • Beta Bionics
  • Beta-O2 Technologies
  • Bigfoot Biomedical
  • Biolinq
  • Cam Med Inc.
  • Dexcom
  • Diabeloop Sa
  • Eli Lilly & Co.
  • Eoflow Inc.
  • Insulet Corp.
  • Lifescan
  • Medtronic Diabetes
  • Nemaura Medical Inc.
  • Pacific Diabetes Technologies
  • Prediktor Medical
  • Roche Diabetes Care
  • Senseonics
  • Tandem Diabetes Care Inc.
  • Tidepool
  • Waveform Technologies

The Report Includes:

  • An overview of the current state of the art for Continuous Glucose Monitoring (CGM) for diabetes
  • Analyses of global market trends with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Encompassing details of CGM functionalities like how they work, who can use one, and when a CGM could help to better manage the disease
  • Examination of the critical issues within the CGM market, including technological developments, geographic trends, market dynamics, adoption trends, and clinical trials
  • Evaluation of current market size, market forecast, and future of the CGM device industry
  • Market share analysis of the leading players of the industry and their comprehensive company profiles

Key Topics Covered:

1 Introduction

2 Executive Summary

  • Overview of the Pancreas
  • T1D and T2D
  • Tight Glycemic Control and the Importance of Time in Range
  • CGMs on the U.S. Market
  • The iCGM Trend
  • Timeline of Recent Device and Software Approvals
  • Increasing Patient Choice and Device Interoperability
  • Advances in the Closed-Loop Insulin Delivery System
  • Tandem's Control-IQ Technology
  • WaveForm Technologies' Cascade CGM
  • Novel Device Developments
  • Smartwatches and Wristbands
  • Implantable CGM Sensors
  • Regulatory and Reimbursement Events
  • FDA Approves New Interoperable Insulin Dosing 'Controller'
  • FDA's 'Breakthrough Device Designation' for Diabetes Management Devices
  • CGM for T2Ds
  • CGM Usage for T2Ds in the European Union
  • Selected Clinical Trials

3 Definitions

  • What Does the Pancreas Do?
  • T1D
  • T2D
  • A Few Statistics
  • Improving Hemoglobin A1c (HbA1c) Control
  • Tight Glycemic Control and the Importance of Time in Range
  • Daily Diabetes-Oriented Tasks of a Person with T1D
  • Advantages of CGM for Managing Glucose Levels
  • How a Diabetic Uses a CGM
  • CGMs Currently on the Market in the EU and U.S.
  • The FDA and ACE Pumps

4 Increasing Patient Choice and Device Interoperability

  • Advances in the Closed-Loop Insulin Delivery System
  • Barriers to a Fully Automated Closed-Loop System
  • Tandem's Control-IQ Technology
  • Tidepool Loop and Interoperable Insulin Pumps
  • Medtronic's Next-Gen Advanced Hybrid Closed Loop System
  • Medtronic's European Envision Pro CGM
  • Biolinq's New CGM Sensor
  • Insulet's Omnipod
  • Dexcom CGM
  • Senseonics and Its Eversense Implantable CGM
  • Lilly: Connected Pens, Dexcom and Hybrid Closed-Loop System
  • WaveForm Cascade CGM
  • Timeline of Recent Device and Software Approvals

5 Novel CGMs and Components in Development

6 Technological Promises or Hype?

7 Selected Regulatory and Reimbursement Affairs

  • The iCGM Trend
  • iCGM Development 'Helped' Along by Hackers
  • iCGM: The Most Important Trend in CGMs
  • FDA Approves New Interoperable Insulin Dosing 'Controller'
  • FDA's 'Breakthrough Device Designation' for Diabetes Management Devices
  • Medicare Supports CGM Smartphone App Use for Diabetes
  • CGM for T2Ds
  • CGMs Have Come Far Since 1999
  • Data Show Improved Glycemic Control in T2Ds
  • CGMs Advanced to the Point of Cost Savings, Even for T2Ds
  • CGM Usage for T2Ds in the European Union
  • Dexcom Granted CE mark for CGM Use by Pregnant Women
  • February 2019: FDA Approves Tandem's and Insulet's ACE Pumps

8 Selected Clinical Trials

9 Company Profiles

10 Appendix: Terms and Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/yd3g11

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900